Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

AbbVie Makes $320M Singapore Expansion

By Drug Discovery Trends Editor | February 6, 2014

AbbVie Inc. announced a $320 million investment to establish operations in Singapore for small molecule and biologics active drug substance manufacturing. The completed facility will provide manufacturing capacity for emerging compounds within AbbVie’s oncology and immunology pipeline to serve markets globally.
 
The investment will establish the first manufacturing presence in Asia by AbbVie. Other AbbVie operations in Asia include research and development (R&D) functions in Tokyo, Japan and Shanghai, China, as well as commercial operations throughout the region. AbbVie’s existing presence in Singapore includes 120 personnel, supporting commercial operations, global R&D and general operations.
 
“As Asia’s fastest-growing bio-cluster, Singapore is an ideal location to expand our manufacturing network while maintaining rigorous standards of quality and delivery for the patients we serve around the world,” said Azita Saleki-Gerhardt, senior vice president, Operations, AbbVie. “Our presence in Singapore will help assure geographic balance and continuity of product supply as well as increased capacity to deliver on our growing biologics and small molecule product pipeline.”
 
“We are very pleased that Singapore will host AbbVie’s first manufacturing facility in Asia. This investment is a testament of Singapore’s strong biologics manufacturing capabilities. To support the continued growth of this sector, Singapore will be investing heavily in human capital development, and new programs will be put in place to train biologics manufacturing talent ahead of demand,” said Kevin Lai, director, Biomedical Sciences of the Singapore Economic Development Board.
 
The investment is expected to result in additional headcount of more than 250 new employees. AbbVie anticipates the new facility will be fully operational by 2019.
 
AbbVie is focused on delivering its small molecule and biologics pipeline to address significant unmet medical needs and advance the wellbeing of patients across the following therapeutic areas: immunology, liver disease, oncology, neuroscience and kidney disease. The company’s unique offerings stem from its 125-year pharmaceutical development heritage combined with the innovative focus of a biotech.
 
AbbVie’s current manufacturing network includes 12 sites across the United States, Europe and Puerto Rico, as well as strategic partnerships with third-party manufacturers.
 
Date: February 5, 2014
Source: AbbVie
 

Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50